DEPO DepoMed Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Depomed, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Depomed, Inc. (NASDAQ: DEPO) from February 26, 2015 through August 7, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Depomed investors under the federal securities laws.

To join the Depomed class action, go to http://rosenlegal.com/cases-1185.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Depomed engaged in questionable practices in connection with the sales and marketing of Depomed’s opioid products; (2) the foregoing conduct, when it became known, would likely subject Depomed to heightened legal and regulatory scrutiny; and (3) as a result, Depomed’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1185.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.

EN
21/08/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on DepoMed Inc.

 PRESS RELEASE

Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics,...

Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc. Name Change Reflects Company’s Focus on Neurology, Orphan and Specialty Businesses LAKE FOREST, Ill., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name change from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” became effective at 11:59 p.m. ET yesterday, August 14, 2018. In connection with the name change, the Company’s common stock will begin trading under a new ti...

 PRESS RELEASE

Depomed Announces Second-Quarter 2018 Financial Results

Depomed Announces Second-Quarter 2018 Financial Results -- Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise -- -- Confirms Regulatory Plan to File for FDA Approval of Cosyntropin Depot by Year End -- -- Announces Agreement with PDL BioPharma to Monetize Royalty Stream; Company Received $20 Million in Cash -- -- Announces Planned Change in Company Name from Depomed to Assertio Therapeutics;Remains On-Track to Transition to New Corporate Headquarters in Lake Forest, Illinois -- LAKE FOREST, Ill., Aug. 0...

 PRESS RELEASE

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, ...

Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018 LAKE FOREST, Ill., July 09, 2018 (GLOBE NEWSWIRE) -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before the open of markets. Following the announcement, the Company will host a conference call beginning at 8:30 a.m. ET to discuss its results. Participants can access the live webcast from the Investor Relations section of Depomed's website at . Please access the website 15 minutes prior to the start of the call to dow...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch